Learn more about S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.
S1613
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and IrinotecN (cetiri) IN Advanced/Medtastatic Colorectal Cancer (mCRC) with HER-2-Amplification Pottstown Hospital Active Clinical Trials
